Clinical trials: Osteogenesis Imperfecta
Osteogenesis Imperfecta
Epigenetic Regulation of Osteogenesis Imperfecta Severity : miROI Study
Osteogenesis Imperfecta (OI) is a heterogeneous group of rare connective tissue hereditary diseases responsible for fragility and bone deformity.
- Trial name
- miROI (NCT04009733)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 66 people
- Sponsor
- Hospices Civils de Lyon
Osteogenesis Imperfecta Type II, Osteogenesis Imperfecta Type III
Repeated Infusions of Mesenchymal Stromal Cells in Children With Osteogenesis Imperfecta
This is a study to evaluate the safety and effectiveness of repeated Mesenchymal Stromal Cells (MSC) infusions to patients with Type II or III osteogenesis imperfecta (OI).
- Trial name
- STOD3 (NCT01061099)
- Testing
- Mesenchymal Stromal Cells
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Nationwide Children's Hospital
Mucopolysaccharidoses, Progressive Pseudorheumatoid Dysplasia
Pediatric Arthropathy Beyond Inflammation: Clinical Spectrum and Diagnostic Approach at Assiut University Children Hospital
To identify the most common underlying causes of non-inflammatory arthropathy in children presenting to Assiut University Children Hospital for through clinical evaluation, laboratory testing, and imaging, in order to improve…
- Conditions
- Mucopolysaccharidoses, Progressive Pseudorheumatoid Dysplasia, Farber Disease, Osteogenesis Imperfecta
- Trial name
- NCT07173010
- Volunteers
- 35 people
- Sponsor
- Assiut University
Osteogenesis Imperfecta
An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
The purpose of this study is to investigate the effect of BPS804 on strength/quality of bone in patients with Type I, III or IV Osteogenesis imperfecta using a special type of CT scanner. Participants will be treated for 1 year.
- Trial name
- Meteoroid (NCT03216486)
- Testing
- BPS804
- Where
- 2 sites in United States
- Sponsor
- Ultragenyx Pharmaceutical Inc
Osteogenesis Imperfecta
Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta
The purpose of this study is to determine the effectiveness of teriparatide (FORTEO), which is human parathyroid hormone 1-34, for increasing bone mass and improving bone structure in adults affected with Osteogenesis Imperfecta…
- Trial name
- OI (NCT00131469)
- Testing
- Teriparatide (FORTEO)
- Where
- 3 sites in United States
- Volunteers
- 79 people
- Sponsor
- Oregon Health and Science University
Osteogenesis Imperfecta
Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)
SAR439459 is a human anti-Transforming growth factor β (TGFβ) monoclonal antibody. This phase 1 clinical study investigates the safety, tolerability, and activity of a single dose of SAR439459 in adult participants with OI.
- Trial name
- NCT05231668
- Testing
- SAR439459
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 16 people
- Sponsor
- Sanofi
Osteogenesis Imperfecta
Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody Denosumab
Pilot study to assess the efficacy of a therapy with the RANKL-antibody denosumab in children 5-10 years of age with mutation in COL1A1 or COL1A2 leading to Osteogenesis imperfecta.
- Trial name
- OI-AK (NCT01799798)
- Testing
- Denosumab
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University of Cologne
Duchenne / Becker Muscular Dystrophy, Osteogenesis Imperfecta (OI)
Social Cognition in Dystrophinopathies and Neurodevelopmental Disorders
The primary aim of this observational study is to investigate specific aspects of social cognition in dystrophinopathies. Body awareness, interpersonal distance and emotional processing will be measured in a sample of patients…
- Conditions
- Duchenne / Becker Muscular Dystrophy, Osteogenesis Imperfecta (OI), Social Cognition
- Trial name
- NCT06874166
- Testing
- Electroencephalography (EEG), Social Cognition Tasks
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- IRCCS Eugenio Medea
Osteoporosis, Cerebral Palsy
Prevention of Post Operative Bone Loss in Children
Hypothesis: one-dose pamidronate will prevent post-operative bone loss in children at risk for low bone density Plan: children with chronic disease such as CP, spina bifida, etc.
- Conditions
- Osteoporosis, Cerebral Palsy, Spina Bifida, Osteopenia
- Trial name
- NCT00655681
- Testing
- pamidronate, saline
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of New Mexico
Osteogenesis Imperfecta
Audio-vestibular Evaluation of Children and Young Adults With Osteogenesis Imperfecta
The aim is to determine whether vestibular deficits are present in OI, then to establish whether a correlation exists between genetic type, severity of OI and audiovestibular phenotype.
- Trial name
- AVOI (NCT05419960)
- Testing
- Vestibular Assessment, Petrous bone Computed Tomography (CT), Magnetic Resonance Imaging (MRI)
- Where
- France
- Volunteers
- 44 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Osteogenesis Imperfecta
Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI
This is a prospective, multicenter, single-arm study in children 2 to 17 years of age with OI to evaluate efficacy and safety of denosumab.
- Trial name
- OI (NCT02352753)
- Testing
- Denosumab
- Where
- 49 sites in United States, Australia and 11 more
- Volunteers
- 153 people
- Sponsor
- Amgen
Osteogenesis Imperfecta
Bisphosphonate Treatment of Osteogenesis Imperfecta
The primary purpose of this trial is to evaluate whether the investigational medication is safe, effective and has the ability to increase spine bone density in osteogenesis imperfecta (OI) patients.
- Trial name
- NCT00063479
- Testing
- Zoledronic Acid
- Where
- 10 sites in United States
- Volunteers
- 158 people
- Sponsor
- Novartis Pharmaceuticals
Osteogenesis Imperfecta
Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta
The primary objective of the study is to evaluate bone mineral density (BMD) after 12 months of retreatment with monthly setrusumab in adults with osteogenesis imperfecta (OI).
- Trial name
- NCT05312697
- Testing
- Setrusumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Osteogenesis Imperfecta, Total Absence of Permanent Teeth
Site Preservation After Tooth Extraction
This study is mainly targeted affected teeth which could not be retained, and patients are willing to undergo implant repair at the later stage.
- Conditions
- Osteogenesis Imperfecta, Total Absence of Permanent Teeth, Tooth Socket
- Trial name
- NCT05258019
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Osteogenesis Imperfecta
Do Bisphosphonates Alter the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta?
Osteogenesis Imperfecta(OI) is an inherited disorder characterised by extreme fragility of the bones. Bones often break from little or no apparent cause.
- Trial name
- BAMES (NCT03208582)
- Testing
- Risedronate Sodium, Calcichew tablets
- Where
- United Kingdom
- Volunteers
- 13 people
- Sponsor
- Sheffield Children's NHS Foundation Trust
Osteogenesis Imperfecta
Nutritional Interventional in Pediatric Patients With Osteogenesis Imperfecta
BACKGROUND: In several bone disorders, adequate calcium intake is a coadjuvant intervention to regular treatment. Osteogenesis imperfecta (OI) is a collagen disorder with a range of symptoms, ranging from fractures to minimum…
- Trial name
- NCT03841188
- Testing
- Nutritional orientation
- Where
- Brazil
- Volunteers
- 52 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Osteogenesis Imperfecta
Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta
The primary objective of the study is to evaluate the effect of setrusumab vs intravenous bisphosphonates (IV-BP) on reduction in fracture rate, including morphometric vertebral fractures in pediatric participants.
- Trial name
- Cosmic (NCT05768854)
- Testing
- Bisphosphonate, Setrusumab
- Where
- 20 sites in United States, Brazil and 5 more
- Volunteers
- 69 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Osteoporosis
GRACE II (General Retrospective Analysis of Commercial Experience With AGN1 LOEP)
The study is designed as a retrospective, multicenter study for subjects previously treated with the AGN1 LOEP Kit in the proximal femur as part of standard hospital practice. This will be a non-randomized and non-blinded study.
- Trial name
- NCT07594639
- Testing
- AGN1 LOEP
- Where
- Belgium
- Volunteers
- 305 people
- Sponsor
- AgNovos Healthcare, LLC
Brittle Bone Disease
Preventive Fixation of Lower Limbs in Osteogenesis Imperfecta (Brittle Bone Disease) With the Highlight of the Fassier-Duval
Osteogenesis imperfecta (or brittle bone disease) is a rare genetic disease characterized by fragile bone and a low mass ossue, secondary to abnormal collagen synthesis. This is a real congenital osteoporosis.
- Trial name
- Fassier-Duval (NCT02868294)
- Testing
- Fassier-Duval Nail
- Where
- France
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Osteogenesis Imperfecta, Short Stature
Natural History of the Collagen-Related Disorder Osteogenesis Imperfecta and Genotype Phenotype Correlation
Background: Osteogenesis Imperfecta (OI) is a connective tissue disorder. OI affects many aspects of a person s health and growth. It can cause frequent fractures, short stature, and bowing of the long bones.
- Trial name
- NCT03575221
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)